Cumberland Pharmaceuticals Inc. a specialty pharmaceutical company with development efforts focused on rare diseases, announced that results from its Phase...
Signal12, Inc., a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treat...
Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune disease, announce the successful completion of thei...
TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regime...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory De...
Dyne Therapeutics, Inc., a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscul...
Amgen announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of UPLIZNA® (inebilizumab-cdon) in adults ...
AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab s...
Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; lis...
Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with E...
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF&rdq...
Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating cardiometabolic diseases driven by obesity, announced the pub...
UCB, a global biopharmaceutical company, announced that Epilepsia published findings from the final analysis of the long-term open-label extension (OLE) st...
© 2025 Biopharma Boardroom. All Rights Reserved.
